Detailansicht

Wissensnetz

Person

Rolf Wachter (1973-)

Kardiologe

Name	Rolf Wachter
Zeit	1973- (Lebensdaten)
Ort	Göttingen (Wirkungsort) Deutschland
Akademischer Grad bzw. Titel	Dr. med.
Beruf	Kardiologe (charakteristischer Beruf)
Variante	Rolf Karl Wachter R. Wachter
Datensatztyp	Person
GND-Nummer	123828600
Datensatz-ID	123828600
Beteiligt an alle anzeigen Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment Circulating miR-let7a levels predict future diagnosis of chronic thromboembolic pulmonary hypertension Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment Impact of the COVID-19 pandemic on implementation of novel guideline-directed medical therapies for heart failure in Germany: a nationwide retrospective analysis Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages Saturated Fatty Acid Blood Levels and Cardiometabolic Phenotype in Patients with HFpEF : A Secondary Analysis of the Aldo-DHF Trial Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction Longitudinal association between N-terminal B-type natriuretic peptide, anxiety and social support in patients with HFpEF: results from the multicentre randomized controlled Aldo-DHF trial The DZHK research platform: maximisation of scientific value by enabling access to health data and biological samples collected in cardiovascular clinical studies Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz (Teil 3) : Körperliches Training und Endothelfunktion Trans-fatty acid blood levels of industrial but not natural origin are associated with cardiovascular risk factors in patients with HFpEF: a secondary analysis of the Aldo-DHF trial Einfluss der Interleukin-6 Inhibition auf die kardiale Funktion transgener herzinsuffizienter Mäuse Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz (Teil 2) : Therapie von Komorbiditäten Comorbidities in heart failure with preserved ejection fraction Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages Attenuation of the heartbeat-evoked potential in patients With atrial fibrillation Sacubitril/valsartan in heart failure : efficacy and safety in and outside clinical trials Patients’ attitude towards a sham-controlled trial on pulmonary vein isolation in atrial fibrillation Expert opinion paper on cardiac imaging after ischemic stroke Expert opinion paper on cardiac imaging after ischemic stroke Heart failure is independently associated with white matter lesions: insights from the population‐based LIFE‐Adult Study Tolerability and feasibility of beta-blocker titration in HFpEF versus HFrEF: Insights from the CIBIS-ELD trial Prospective multicentric validation of a novel prediction model for paroxysmal atrial fibrillation Higher galectin-3 levels are independently associated with lower anxiety in patients with risk factors for heart failure The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM‐CHF randomized controlled trial Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction Heterogeneous Metabolic Response to Exercise Training in Heart Failure with Preserved Ejection Fraction Natriuretic peptides for the detection of paroxysmal atrial fibrillation Expert opinion paper on atrial fibrillation detection after ischemic stroke Aktualisierte ESC-Leitlinie: Pharmakotherapie der chronischen Herzinsuffizienz : Epidemiologie und Krankheitsbild, Pathophysiologie und Risikofaktoren, ESC-Therapiealgorithmus Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study GDF-15, MRproADM, CTproET1 und CTproAVP bei Patienten mit asymptomatischer diastolischer Dysfunktion Herzinsuffizienz mit erhaltener LV-Funktion Cost-effectiveness of 7-day-Holter monitoring alone or in combination with transthoracic echocardiography in patients with cerebral ischemia Diagnostik und Therapie der diastolischen Herzinsuffizienz : 22 Tabellen Antiarteriosklerotische Eigenschaften von Nifedipin in der Gefäßwand - ein kalziumantagonistischer Effekt?

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Rolf Wachter (1973-)

Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment

Circulating miR-let7a levels predict future diagnosis of chronic thromboembolic pulmonary hypertension

Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment

Impact of the COVID-19 pandemic on implementation of novel guideline-directed medical therapies for heart failure in Germany: a nationwide retrospective analysis

Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages

Saturated Fatty Acid Blood Levels and Cardiometabolic Phenotype in Patients with HFpEF : A Secondary Analysis of the Aldo-DHF Trial

Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction

Longitudinal association between N-terminal B-type natriuretic peptide, anxiety and social support in patients with HFpEF: results from the multicentre randomized controlled Aldo-DHF trial

The DZHK research platform: maximisation of scientific value by enabling access to health data and biological samples collected in cardiovascular clinical studies

Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz (Teil 3) : Körperliches Training und Endothelfunktion

Trans-fatty acid blood levels of industrial but not natural origin are associated with cardiovascular risk factors in patients with HFpEF: a secondary analysis of the Aldo-DHF trial

Einfluss der Interleukin-6 Inhibition auf die kardiale Funktion transgener herzinsuffizienter Mäuse

Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial

Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz (Teil 2) : Therapie von Komorbiditäten

Comorbidities in heart failure with preserved ejection fraction

Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages

Attenuation of the heartbeat-evoked potential in patients With atrial fibrillation

Sacubitril/valsartan in heart failure : efficacy and safety in and outside clinical trials

Patients’ attitude towards a sham-controlled trial on pulmonary vein isolation in atrial fibrillation

Expert opinion paper on cardiac imaging after ischemic stroke

Expert opinion paper on cardiac imaging after ischemic stroke

Heart failure is independently associated with white matter lesions: insights from the population‐based LIFE‐Adult Study

Tolerability and feasibility of beta-blocker titration in HFpEF versus HFrEF: Insights from the CIBIS-ELD trial

Prospective multicentric validation of a novel prediction model for paroxysmal atrial fibrillation

Higher galectin-3 levels are independently associated with lower anxiety in patients with risk factors for heart failure

The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM‐CHF randomized controlled trial

Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction

Heterogeneous Metabolic Response to Exercise Training in Heart Failure with Preserved Ejection Fraction

Natriuretic peptides for the detection of paroxysmal atrial fibrillation

Expert opinion paper on atrial fibrillation detection after ischemic stroke

Aktualisierte ESC-Leitlinie: Pharmakotherapie der chronischen Herzinsuffizienz : Epidemiologie und Krankheitsbild, Pathophysiologie und Risikofaktoren, ESC-Therapiealgorithmus

Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study

GDF-15, MRproADM, CTproET1 und CTproAVP bei Patienten mit asymptomatischer diastolischer Dysfunktion

Herzinsuffizienz mit erhaltener LV-Funktion

Cost-effectiveness of 7-day-Holter monitoring alone or in combination with transthoracic echocardiography in patients with cerebral ischemia

Diagnostik und Therapie der diastolischen Herzinsuffizienz : 22 Tabellen

Antiarteriosklerotische Eigenschaften von Nifedipin in der Gefäßwand - ein kalziumantagonistischer Effekt?